AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06675461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gold Card Intervention
Description: A 4-session manualized intervention consisting of weekly scheduled 50-minute 1:1 sessions focused on psycho-education, here-and-now problem solving and safety planning. One of the sessions can involve a significant other to provide psychoeducation about the disorder and to facilitate support.
Study NCT06675461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Access to psychiatric assessment, medication review, and unscheduled sessions with allied health professionals using a drop-in model of care.
Study NCT06690307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled intravenous analgesia(PCIA)
Description: Patients will receive sulfentanil for PCIA.
Study NCT06690307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient controlled intravenous analgesia(PCIA)
Description: Patients will receive oxycodone for PCIA.
Study NCT06714981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Free Anaesthesia
Description: patients received opioid free anesthesia
Study NCT06714981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid based Anesthesia
Description: patients received opioid based anesthesia
Study NCT06712836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET097
Description: MET097 is an ultra-long-acting, fully-biased analog of human GLP-1.
Study NCT06712836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% (w/v) saline will be used as placebo treatment during the study.
Study NCT06710210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCI with a bioresorbable scaffold and drug-coated balloon(s)
Description: Hybrid PCI combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland)
Study NCT06710210 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PCI with drug-eluting stent(s)
Description: PCI with >1 newer-generation drug-eluting stent (Orsiro Mission, Biotronik AG, Switzerland)
Study NCT06719492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutrition education
Description: 15 minutes of surgery specific nutrition education provided by a Registered Dietitian.
Study NCT06718023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nordic walking
Description: NW training sessions are conducted by a certified NW instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, each interval of 1 or 2 days, a total of 12 weeks. Participants used professional Nordic Pole.
Study NCT06718023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
Study NCT06718023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bungy Pump Exercises
Description: Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, , a total of 12 weeks. Participants used professional Bungy Pump Pole.
Study NCT06719193 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Enhanced community-wide TB intervention
Description: Interventions in the intervention arms consist of the following key components:~1. an optimized national recommended set of interventions; such as the implementation of all types of contact investigation, targeted TB screening and diagnosis at key affected population, and optimized HIV screening and TPT for PLHIV;~2. intensive, active, and community-based HH screening and diagnosis of TB using combined TB screening (clinical and X-ray) and X-pert MTB/RIF, as indicated;~3. community-based enhanced TPT; and~4. community-based awareness creation and health education using the community social associations.
Study NCT06719193 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Routine TB program activities
Description: In the control arm, the standard of care will continue per the national guideline.
Study NCT04475991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc+Favipiravir+CT
Description: Maraviroc tablets. 300 mg bid, given orally for a 10 day period AND Favipiravir tablets 200 mg. given orally for the first 7 days. 1600 mg bid on day 1 and 600 mg tid days 2-7 AND CT (Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present, as per currently used at Hospital General de México Dr. Eduardo Liceaga)
Study NCT06717243 — intervention group
Intervention type: DRUG
Intervention: Carboplatin/Cisplatin -Etoposide - Atezolizumab
Description: This intervention represents the standard-of-care first-line treatment regimen for extensive-stage small cell lung cancer (ES-SCLC). The regimen includes:~Carboplatin or Cisplatin: Platinum-based chemotherapeutic agents that cause DNA cross-linking, leading to tumor cell death.~Etoposide: A topoisomerase II inhibitor that prevents DNA replication and tumor growth.~Atezolizumab: A PD-L1 immune checkpoint inhibitor that enhances the immune system's ability to detect and destroy cancer cells.~This combination therapy is administered as part of routine clinical practice. The study does not investigate the efficacy or safety of these drugs but rather focuses on analyzing molecular changes in tumors, such as genomic and epigenetic alterations, to understand mechanisms of treatment resistance. Biospecimens are collected from patients during treatment and progression for detailed analysis.
Study NCT06716996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repeated transcranial magnetic stimulation
Description: 20 sessions of repeated transcranial magnetic stimulation
Study NCT06716996 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham treatment
Description: 20 sessions of sham treatment
Study NCT06717282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual rehabilitation for ophthalmic compliance
Description: contextual, behavioral, and cognitive-based program for ophthalmic compliance
Study NCT06717282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using contextual, behavioral, and cognitive-based stragegies to develop training programs
Description: Key Features of the Intervention:~1. Contextual Adaptation: Participants practice ophthalmic examination procedures in a simulated clinical environment to familiarize themselves with real-world conditions.~2. Behavioral Strategies: Positive reinforcement, such as rewards (snacks, toys, or videos), is used to encourage participation and cooperation during sessions.~3. Cognitive Support: Animated materials and interactive exercises are employed to teach the concepts required for visual tests, with take-home tasks for generalization.~4. Individualized Goals: Individualized training plans and objectives are established collaboratively with caregivers based on participants' cognitive and behavioral profiles.~Duration and Frequency:~Six sessions, each lasting one hour, are conducted biweekly, with flexibility based on caregiver availability.
Study NCT06712680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product HYP-6589
Description: HYP-6589 should be administered orally at the recommended dosage
Study NCT06719167 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychoterapy
Description: During 11 weeks admission the programme will include group sessions using different modalities (psychoeducation videos, live psychoeducation groups, expressive arts therapy, equine facilitated therapy, mindfulness and discussion groups) all using TIST methodology. Parallell individual therapy with therapist (psychologist or psychiatrist) and milieu therapist. All therapists will be trained minimum in TIST level 1 and recieve supervision from an expert TIST therapist.
Study NCT06716515 — intervention group
Intervention type: DEVICE
Intervention: digital inclinometer
Description: Digital inclinometer to assess gender difference in knee repositioning error
Study NCT06716775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor treating felds (TTF)
Description: Tumor Treating Fields will be administered continuously with a planned ≥ 18 h per day.
Study NCT06716775 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Standard of Care
Description: Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.
Study NCT06716775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Standard of Care
Description: Patients will be treated with the best known standard of care for NSCLC brain metastasis and undergo SRS alone.
Study NCT05498584 — intervention group
Intervention type: BEHAVIORAL
Intervention: exercise based cardiac rehabilitation
Description: The types of exercise are treadmill walking/walking-jogging/jogging, ergometer cycling, stair climbing, or elliptical machine training. The training intensity is gradually increased fortnightly to reach the targeted Borg's rate of perceived exertion (RPE) of 12-14. The training duration is 40 minutes, which included 5-10 minutes of warm-up and cool-down exercises. The training frequency is three sessions per week, with 36 sessions concluding a complete course.
Study NCT05446714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CH 4 band
Description: expansion of maxilla and observation improvement of the air way
Study NCT05446714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HH 2 bands
Description: expansion of maxilla and observation improvement of the air way
Study NCT05446714 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MSE 2 bands and 4
Description: expansion of maxilla and observation improvement of the air way
Study NCT05916300 — intervention group
Intervention type: OTHER
Intervention: Diagnostic ultrasonography-guided physiotherapy group
Description: All participants will complete free 10 outpatient 30-minute sessions. The therapy will be focused on increasing the range of motion and muscle strength, optimizing the function of the lower limbs, reducing possible complications of post-traumatic conditions in the ankle area.~The physiotherapy procedures of the intervention group will be modified based on the initial diagnostic ultrasonography examination.
Study NCT05095298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccine, COVID19
Description: It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
Study NCT05923697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AF-EMDR
Description: Investigational treatment~All participants receive four 90 min. AF-EMDR sessions within a timeframe of two weeks following the baseline phase. The AF-EMDR treatment will be provided by the principal investigators, a level II EMDR therapist (RvdH) and an EMDR consultant in training who developed the AF-EMDR protocol. The EMDR therapist (RvdH) will be trained by the EMDR consultant (WM), who is available for consultation. Additionally, both participate monthly in peer-supervision whereby videotaped sessions are discussed. See appendix 1 for a detailed understanding of the AF-EMDR protocol.
Study NCT05989568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASIS-T
Description: BASIS-T is designed to address the behavioral components often missing from standard EBPP training and consultation that relate to motivation prior to receiving EBPP training, and volition after EBPP training. It is an EBPP-agnostic implementation strategy designed to be delivered within the Preparation/Adoption phase, immediately prior to Active Implementation (CITE EPIS). BASIS-T targets behavioral intentions via improvement in attitudes, subjective norms, and self-efficacy.
Study NCT05989568 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control (ACC)
Description: Teachers assigned to the ACC will receive pre- and post-training experiences designed to mirror those received in the BASIS-T condition. These training experiences will be virtual, delivered by the same interventionist, and be approximately the same length as the BASIS-T experiences, but will not contain any of the BASIS-T content or mechanisms of change. The ACC pre-training experience will define, describe, and advocate for EBP implementation in schools. Content will be didactic, as is typical in professional development training for teachers.
Study NCT06423391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuOst
Description: As above
Study NCT06423391 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Description: As above
Study NCT06423391 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: As above
Study NCT05986773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
Study NCT05986773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
Study NCT05986773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Two to five hours after the initial standard dose Furosemide i.v, the patients are randomized towards 3 study-specific diuretic regimens: the first group will receive a doubled dose Furosemide i.v. (group FF), the second group will receive a combination of standard dose Furosemide i.v. and Metolazone 5 mg p.o. (group FM), the third group will receive a combination of standard dose Furosemide i.v. and Acetazolamide 500 mg i.v. (group FA).
Study NCT05823896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nirmatrelvir/ritonavir
Description: 300/100 mg tablet twice daily (q12h) administered orally for 15 days
Study NCT05823896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/ritonavir
Description: 100mg tablet twice daily (q12h) administered orally for 15 days
Study NCT05848778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia
Description: The acute intermittent hypoxia protocol will consist of 15 cycles of 1.5 min of inspiring ambient air (21% O2) alternating with 1.5 min of hypoxic air (9% O2)
Study NCT05848778 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normoxia
Description: The normoxia protocol will consist of 15 cycles of 3 min of inspiring ambient air (21% O2)
Study NCT06102655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiajian Guishen Formulation
Description: Jiajian Guishen Formulation is a formulation of Traditional Chinese Medicine.POI patients will be treat with Jiajian Guishen Formulation for three menstrual cycles; their blood samples are collected before and after treatment.No drug will be used in control group, and their blood samples are collected when join the experiment.
Study NCT05068349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Description: Butylphthalide sodium chloride injection 25mg, 2 times a day, 7-14 days, followed by 0.2g butylphthalide soft capsules, 3 times a day, 76-83 days, a total of 90 days.
Study NCT05987124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: HCT recipients with SOS/VOD and renal and/or pulmonary dysfunction with either PR after 21 days of standard doses of defibrotide (25mg/kg/day) or SD, after 14 days of standard doses of defibrotide (25mg/kg/day) progressive disease after 7 days on defibrotide (25mg/kg/day) will undergo intra-patient dose escalation every 4 days until a complete response is obtained up until the highest dose level of 100mg/kg/day at which point an endpoint of CR, PR or SD will be sought(Maximum of 4 dose levels). Defibrotide will be administered in D5W or 0.9% NaCl via IV infusion over 2 hours q6 hours.
Study NCT05111145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination tablets for oral administration.
Study NCT05111145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablets for oral administration.
Study NCT05009121 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: At first, each person will be asked basic questions about present feelings according to their condition using a questionnaire. Than he/she will be tested by the Box and Block Test according to the Czech version of extended manual for this test in only one session. Audio recording of verbal instructions will be used.~The results will be used only for establishing of the variability and inter-rater reliability of the Box and Block Test, not for patients' other interventions.
Study NCT05572450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 1
Description: Approximately 10\^5.5 TCID50/mL (titre may be adjusted based on stock titre)
Study NCT05572450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 2
Description: Approximately 10\^4.5 TCID50/mL (titre may be adjusted based on stock titre)
Study NCT05572450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 3
Description: To be determined (TBD), depending on outcome of Part A
Study NCT05572450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infectious Titre 4
Description: TBD, depending on outcome of Part A
Study NCT05789810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel pressure
Description: 10-second manual pressure was applied on the insulin injection area.
Study NCT05789810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Description: ShotBlocker device was placed in the insulin injection site by contacting the protruding surface with the skin and was kept throughout the injection. The injection was applied through the opening at the middle of the tool.
Study NCT05789810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention was performed to reduce pain and fear.
Study NCT06312345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: ciprofol injection
Description: Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
Study NCT06312345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: ciprofol injection
Description: Patients in ciprofol group 0.3 mg/kg ciprofol for induction of anesthesia
Study NCT04028921 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional study; no intervention
Study NCT06358495 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Digital CBT-I is an online, six-module, self-guided CBT-I intervention. It includes videos and read information on behavioral (e.g., stimulus control, relaxation) and cognitive (e.g., restructuring, reducing arousal, and problem-solving) techniques, as well as psychoeducation (e.g., sleep hygiene). Participants complete homework following each session and track their sleep using an online diary. Young people could choose to involve their parents, for example, through completing sessions together. However, we will add a virtual session for parents as their involvement may improve adolescent engagement with the intervention as well as outcomes for adolescent sleep problems (Gradisar et al., 2011). This module will include an overview of the program components (behavioural, cognitive, and educational), goals and homework, and addresses parents' beliefs about sleep.
Study NCT06358495 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants are encouraged to continue any care they are already receiving and will be placed on a wait-list for digital CBT-I after their final assessment. All activities participants try for improving their own sleep problems between assessments will be recorded and coded for.
Study NCT05240313 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: kiR venezolano
Description: A multi-week intervention focused on drug refusal skills and self-regulation.
Study NCT05240313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: kiR venezolano
Description: A multi-week intervention focused on drug refusal skills and self-regulation.